Аннотация
Escherichia coli является одним из ведущих возбудителей нозокомиальных инфекций. В последние годы отмечается возрастание резистентности данного возбудителя к антибиотикам. В ходе исследования была изучена резистентность 388 нозокомиальных штаммов E. coli, выделенных в отделениях реанимации и интенсивной терапии (ОРИТ) различных регионов России в 2002-2004 гг., и 124 штаммов, выделенных в 2006-2008 гг. Исследована резистентность к амикацину, амоксициллину/клавуланату, ампициллину, гентамицину, дорипенему, имипенему, котримоксазолу, левофлоксацину, меропенему, моксифлоксацину, нетилмицину, пиперациллину, пиперациллину/тазобактаму, тикарциллину/клавуланату, цефепиму, цефоперазону, цефоперазону/сульбактаму, цефотаксиму, цефтазидиму, цефтриаксону, ципрофлоксацину, фосфомицину, эртапенему. Максимальную активность проявили карбапенемы (имипенем, меропенем, эртапенем, дорипенем): количество нечувствительных к ним штаммов составляло 0-0,5%. Количество продуцентов β-лактамаз расширенного спектра составляло 49,7% в 2002-2004 гг. и 76,6% в 2006-2008 гг.
-
1.
Sweeney N. J., Klemm P., McCormick B.A., et al. The Escherichia coli K-12 gntP gene allows E. coli F-18 to occupy a distinct nutritional niche in the streptomycin-treated mouse large intestine. Infect Immun 1996; 64:3497-503.
-
2.
McBean M., Rajamani S. Increasing rates of hospitalization due to septicemia in the US elderly population, 1986- 1997. J Infect Dis 2001; 183:596-603.
-
3.
Gransden W., Eykyn S., Phillips I., Rowe B. Bacteremia due to Escherichia coli: A study of 861 episodes. Rev Infect Dis 1990; 12:1008-18.
-
4.
Roberts F., Geere I., Coldman A. A three-year study of positive blood cultures, with emphasis on prognosis. Rev Infect Dis 1991; 13:34–46.
-
5.
Vastag B. New vaccine decreases rate of nosocomial infections. JAMA 2001; 285:1565.
-
6.
Siegman-Igra Y., Fourer B., Orni-Wasserlauf R., et al. Reappraisal of comminity-acquired bacteremia: A proposal of a new classification for the spectrum of acquisition of bacteremia. Clin Infect Dis 2002; 34:1431–39.
-
7.
Russo T., Johnson J. Medical and economic impact of extraintestinal infections due to Escherichia coli: an overlooked epidemic. Microbes and Infect 2003;5:449–56.
-
8.
Minino A., Smith B. Deaths: Preliminary data for 2000. National Vital Statistics Reports 2001; 49:1–40.
-
9.
Fluit A., Schmitz F., Verhoef J., Group ESP. Frequency of isolation of pathogens from bloodstream, nosocomial pneumonia, skin and soft tissue, and urinary tract infections occurring in European patients. Eur J Clin Microbiol Infect Dis 2001; 20:188–91.
-
10.
Bernard G., Vincent J., Laterre P., et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699–709.
-
11.
Neuhauser M.M., Weinstein R.A., Rydman R., Danziger L.H., Karam G., Quinn J.P. Antibiotic resistance among gram-negative bacilli in US intensive care units. JAMA 2003; 289: 885-8.
-
12.
Kramer A., Schwebke I., Kampf1 G. How long do nosocomial pathogens persist on inanimate surfaces? A systematic review. BMC Infectious Diseases 2006, 6:130.
-
13.
National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing: 14th informational supplement. NCCLS document M100-S14. 2004. National Committee for Clinical Laboratory Standards, Wayne, PA.
-
14.
Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: 16th informational supplement. CLSI document M100-S16. 2008. Clinical and Laboratory Standards Institute, Wayne, PA.
-
15.
National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing: 13th informational supplement. NCCLS document M100-S13 2003. National Committee for Clinical Laboratory Standards, Wayne, PA.
-
16.
Методические указания МУК 4.2.1890-04 «Определение чувствительности микроорганизмов к антибактериальным препаратам». 2004.
-
17.
Garcia-Rodriguez J.-A., Jones R.N. and the MYSTIC Programme Study Group. Antimicrobial resistance in gram-negative isolates from European intensive care units: data from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Prorgramme. J Chemother 2002; 14:25-32.
-
18.
Rhomberg P.R., Jones R.N. Contemporary activity of meropenem and comparator broad-spectrum agents: MYSTIC program report from the United States component (2005). Diagn Microbiol Infect Dis 2007; 57:207- 215.
-
19.
Lockhart S.R., Abramson M.A., Beekmann S.E., et al. Antimicrobial resistance among Gram-negative bacilli causing infections in intensive care unit patients in the United States between 1993 and 2004. J Clin Microbiol 2007; 45:3352-9.
-
20.
Reinert R.R., Low D.E., Rossi F., Zhang X., Wattal C., Dowzicky M.J. Antimicrobial susceptibility among organisms from the Asia/Pacific Rim, Europe and Latin and North America collected as part of TEST and the in vitro activity of tigecycline. J Antimicrob Chemother 2007; 60:1018-29.
-
21.
Hoban D., Bouchillon S., Johnson B., et al. Tigecylcine in vitro activity in current European pathogens - T.E.S.T. Programm 2006. Abstract P490. In: Programs and Abstracts of the 16th European Congress of Clinical Microbiology and Infectious Diseases, Nice, France, 2006.
-
22.
Cermak P., Kolar M., Latal T. Frequency of gram-negative bacterial pathogens in bloodstream infections and their resistance to antibiotics in the Czech Republic. Intern J Antimicrob Agents 2004; 23:401-404.
-
23.
Nijssen S., Florjin A., Bonten M.J.M., Schmitz F.J., Verhoef J., Fluit A.C. Beta-lactam susceptibilities and prevalence of ESBL-producing isolates among more than 5000 European Enterobacteriaceae isolates. Int J Antimicrob Agents 2004; 24:585-591.
-
24.
Streit J.M., Jones R.N., Sader H.S., Fritshce T.R. Assessment of pathogen occurrence and resistance profiles among infected patients in the intensive care unit: report from the SENTRY Antimicrobial Surveillance Programm (North America, 2001). Int J Antimicrob Agents 2004; 24: 111-8.
-
25.
Livermore D.M., Canton R., Gniadkowski M., et al. CTXM: changing the face of ESBLs in Europe. J Antimicrob Chemother 2007;59:165-74.
-
26.
Эйдельштейн М.В., Страчунский Л.С., исследовательская группа РОСНЕТ. Динамика распространённости и чувствительности БЛРС–продуцирующих энтеробактерий к различным антимикробным препаратам в ОРИТ России. Клиническая Микробиология и Антимикробная Химиотерапия. 2005; 7(4):323-36.
-
27.
Gales A.C., Jones R.N., Sader H.S. Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001- 2004). Clin Microbiol Infect 2006; 12:315-21.